StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Aditya Agarwal, Coheron Brokers

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byAditya Agarwal, Coheron BrokersHorizon: NA (inferred Swing (≤2wk))22 Oct 2026via Business Today

Entry₹1,244.6Inferred
Target₹1,340
Total upside +7.67%
Stop loss₹1,200-3.58% risk
CMP₹1,227.7Just now
Active-1.36%+9.15%upside left 13d left
Follow Aditya Agarwal for new calls(32% target hit, 19 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 3 other Swing calls on DRREDDYSee 130 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 1:51 pm IST
5 supporting2 neutral5 opposing
Supports the BUY call (5)

4 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·22 Oct · today

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · yesterday

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · yesterday

(opens in new tab)

Dr. Reddy's Laboratories received approval from the DCGI for Zytorvi (toripalimab) in combination with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma in India.

BSE · Company Update·21 Oct · yesterday

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·11 Aug · 2mo ago

Neutral / worth noting (2)

Q2 FY27 results scheduled — board meets 23 Oct 2026

BSE · Board Meeting·In 1 day

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3d ago

(opens in new tab)
Weighs against the BUY call (5)

MACD below its signal line — bearish momentum

Technicals · macd·22 Oct · today

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 2w ago

(opens in new tab)

A pre-approval inspection ends with USFDA observations at Dr. Reddy’s (RDY).

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Dr. Reddy's USFDA PAI Inspection: Form 483 at FTO-11 Plant

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Pomerantz LLP investigates Dr. Reddy's over semaglutide-linked losses

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Aditya Agarwal, Coheron Brokers

Every call and its outcome